Patient-Derived Cell Assays: A Translational Approach to Evaluating IPF Therapies

Idiopathic pulmonary fibrosis (IPF) is a rare fatal lung disease where myofibroblasts cause progressive scarring of lung tissues. Current therapies primarily focus on symptom management and do not slow disease progression, leaving an unmet clinical need for disease-modifying therapies.

View our webinar to learn how we’re using lung cells derived from IPF patients and healthy donors to create in vitro fibrosis assays that are useful readouts in the assessment of novel therapies for this devastating disease.


  • Krista Ouwehand, PhD, Team Leader, Biology, Charles River

Related Resources